SCHEMBL16872914

SCHEMBL16872914

O=C(O)C1Nc2ccc(OCc3ccc(Cl)cc3Cl)cc2C2C=CCC12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 14/20 0.69
CDC25B P30305 2/20 0.69
HSPA1A P0DMV8 13/20 0.62
MCL1 Q07820 3/20 0.59
BCL2L1 Q07817 1/20 0.59
GAPDH P04406 9/20 0.54
POLB P06746 6/20 0.54
KMT2A Q03164 6/20 0.54
MEN1 O00255 5/20 0.54
BLM P54132 4/20 0.54
L3MBTL1 Q9Y468 4/20 0.54
TDP1 Q9NUW8 4/20 0.54
ALDH1A1 P00352 3/20 0.54
MASP2 O00187 3/20 0.54
KDM4E B2RXH2 2/20 0.54
MAPT P10636 2/20 0.54
HPGD P15428 2/20 0.54
ALOX15 P16050 2/20 0.54
BRCA1 P38398 2/20 0.54
RECQL P46063 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3610631 0.82 CDC25B (1.00) PTPN7CDC25BHSPA1AMCL1BCL2L1
SCHEMBL12768063 0.82 PTPN7 (1.00) PTPN7CDC25BHSPA1AMCL1BCL2L1
SCHEMBL13725197 0.76 PTPN7 (0.58) PTPN7CDC25BHSPA1AMCL1GAPDH
SCHEMBL16883499 0.73 PTPN7 (0.83) PTPN7CDC25BHSPA1AMCL1BCL2L1
SCHEMBL6215376 0.72 POLB (0.77) PTPN7CDC25BHSPA1AMCL1BCL2L1
SCHEMBL2116528 0.71 PTPN7 (1.00) PTPN7CDC25BHSPA1AMCL1BCL2L1
SCHEMBL16706087 0.71 PTPN7 (1.00) PTPN7CDC25BHSPA1AMCL1BCL2L1
SCHEMBL2808722 0.71 PTPN7 (1.00) PTPN7CDC25BHSPA1AMCL1GAPDH
SCHEMBL13056448 0.69 PTPN7 (1.00) PTPN7CDC25BHSPA1AMCL1GAPDH
SCHEMBL6087749 0.69 HSPA1A (1.00) PTPN7CDC25BHSPA1AMCL1GAPDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170348295-A1 SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA SIRGA ADVANCED BIOPHARMA INC (US) 2017-12-07 US disclosed
US-9775835-B2 Small molecule inhibitors of viral protein interactions with human t-RNA SIRGA ADVANCED BIOPHARMA, INC. (US) 2017-10-03 US disclosed
US-20150190384-A1 SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA SIRGA ADVANCED BIOPHARMA, INC. (US) 2015-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348295-A1 SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA NSUN3, TARBP1, TRDMT1 PTPN7 2917/4885CDC25B 3421/4885HSPA1A 2079/4885
US-20150190384-A1 SMALL MOLECULE INHIBITORS OF VIRAL PROTEIN INTERACTIONS WITH HUMAN T-RNA NSUN3, TARBP1, TRDMT1 PTPN7 2873/4885CDC25B 3506/4885HSPA1A 2061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.